Compare CET & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | IOVA |
|---|---|---|
| Founded | 1929 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | CET | IOVA |
|---|---|---|
| Price | $53.36 | $3.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 38.9K | ★ 14.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.77 | $1.64 |
| 52 Week High | $54.28 | $5.63 |
| Indicator | CET | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 50.41 |
| Support Level | $50.64 | $2.05 |
| Resistance Level | $53.88 | $4.27 |
| Average True Range (ATR) | 0.70 | 0.25 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 54.68 | 42.61 |
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.